E. DEMİRCİ Et Al. , "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels," European Journal of Clinical Pharmacology , vol.78, no.7, pp.1095-1104, 2022
DEMİRCİ, E. Et Al. 2022. A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels. European Journal of Clinical Pharmacology , vol.78, no.7 , 1095-1104.
DEMİRCİ, E., ŞENER, E. F., Gul, M. K., ÖNAL, M. G., & Dal, F., (2022). A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels. European Journal of Clinical Pharmacology , vol.78, no.7, 1095-1104.
DEMİRCİ, ESRA Et Al. "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels," European Journal of Clinical Pharmacology , vol.78, no.7, 1095-1104, 2022
DEMİRCİ, ESRA Et Al. "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels." European Journal of Clinical Pharmacology , vol.78, no.7, pp.1095-1104, 2022
DEMİRCİ, E. Et Al. (2022) . "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels." European Journal of Clinical Pharmacology , vol.78, no.7, pp.1095-1104.
@article{article, author={ESRA DEMİRCİ Et Al. }, title={A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels}, journal={European Journal of Clinical Pharmacology}, year=2022, pages={1095-1104} }